Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 209

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 209
---
:|:--|
| Cash Flow Data:                                          |     |                         |         |   |     |      |         |   |
| Net cash proceeds from (used for) operating activities   |     | $                       |  19,349 |   |     | $    | (20,707 | ) |
| Net cash used for investing activities                   |     |                         |  (2,675 | ) |     |      |    (330 | ) |
| Net cash (used for) proceeds from financing activities   |     |                         | (18,131 | ) |     |      |  23,582 |   |
| Net change in cash, cash equivalents and restricted cash |     | $                       |  (1,457 | ) |     | $    |   2,545 |   |

Cash Flows from Operating Activities For the year ended December 31, 2024, net cash proceeds from operating activities was approximately $19.3 million, attributable to non-cashreconciling items of $27.3 million related to allocated expense for financial instruments at fair value, stock-based compensation, change in fair value of debt and liability instruments, allowances for expected credit losses, depreciation and amortization, non-cashoperating lease cost and gain on derivative liabilities, and changes in operating assets and liabilities that provided $64.8 million of cash, partially offset by our net loss of $72.8 million. For the year ended December 31, 2023, net cash used for operating activities was approximately $20.7 million, attributable to our net loss of $114.3 million, partially offset by other non-cashreconciling items of $27.9 million related to loss on derivative liabilities, stock-based compensation, change in fair value of debt and liability instruments, depreciation and amortization and non-cashoperating lease cost, and changes in operating assets and liabilities that provided $65.7 million of cash. Cash Flows from Investing Activities For the year ended December 31, 2024, net cash used for investing activities was approximately $2.7 million and was related to $0.6 million payments of deferred consideration for Romeg intangible asset acquisition under the Romeg License Agreement, $2.0 million purchase of the Class B ordinary shares of Denali and $0.1 million purchase of a convertible promissory note from Denali (see Note 5 titled “ Balance Sheet Components” to our consolidated financial statements included elsewhere in